Ä¢¹½ÊÓÆµis pleased to have represented Ocuvex Therapeutics, Inc., a biopharmaceutical company specializing in ophthalmic therapeutics, in its Merger Agreement with Onconetix, Inc. (Nasdaq: ONCO). Under the Merger Agreement, Onconetix will acquire all Ocuvex equity interests in exchange for newly-issued Onconetix shares, resulting in Ocuvex equity holders owning 90% of the combined company, subject to […]
Ä¢¹½ÊÓÆµrepresented Aptitude 8, an Elite level HubSpot Global Partner, in its combination with OBO, establishing a premier HubSpot technical consulting firm. The transaction is the latest in the firm’s work with technology services clients in a M&A matters and a range of corporate transactions and agreements. Corporate attorneys Larry Tauber, Daniel Arbov, and Russ […]
Ä¢¹½ÊÓÆµrepresented Regor Pharmaceuticals in its sale of next-generation CDK inhibitors for breast cancer treatment to Genentech (a Roche Group member) for an upfront payment of $850 million plus milestone payments. Ä¢¹½ÊÓÆµadvised on all aspects of the negotiation and transaction. We are proud to support impactful transactions driving pharmaceutical innovation.